Crossmark

Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors

Crossref DOI link: https://doi.org/10.1016/j.gastrohep.2022.10.021

Published Print: 2023-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Davis González, María Rocío

Ballester, María Pilar http://orcid.org/0000-0001-7177-5696
Romero-González, Eva

Sánchez-Pardo, Ana María

Marti-Aguado, David

Tosca, Joan

Suria, Carles

Antón Ausejo, Rosario

Pascual Moreno, Isabel

Planelles Silvestre, María Dolores

Mínguez Pérez, Miguel

Bosca-Watts, Marta Maia
Funding

Funding for this research was provided by:

Instituto de Salud Carlos III

Ministerio de Ciencia e Innovación

AbbVie

Meso Scale Diagnostics

Ferring Pharmaceuticals
License Information

Text and Data Mining valid from 2023-11-01

stm-asf valid from 2023-11-01

stm-asf valid from 2023-11-01

stm-asf valid from 2023-11-01

stm-asf valid from 2023-11-01

stm-asf valid from 2023-11-01
More Information

This article is maintained by: Elsevier

Article Title: Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors

Journal Title: Gastroenterología y Hepatología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastrohep.2022.10.021

Content Type: article

Copyright: © 2022 Elsevier España, S.L.U. All rights reserved.